Show simple item record

dc.contributor.authorChen, L
dc.contributor.authorWang-Gillam, A
dc.contributor.authorLi, C
dc.contributor.authorBodoky, G
dc.contributor.authorDean, A
dc.contributor.authorShan, Y
dc.contributor.authorJameson, G
dc.contributor.authorMacarulla, T
dc.contributor.authorLee, K
dc.contributor.authorCunningham, D
dc.contributor.authorBlanc, J
dc.contributor.authorHubner, Richard A
dc.contributor.authorChiu, C
dc.contributor.authorSchwartsmann, G
dc.contributor.authorBraiteh, F
dc.contributor.authorBelanger, B
dc.contributor.authorBayever, E
dc.contributor.authorde Jong, F
dc.contributor.authorVon Hoff, D
dc.contributor.authorSiveke, J
dc.date.accessioned2017-05-01T20:28:24Z
dc.date.available2017-05-01T20:28:24Z
dc.date.issued2016-10-01
dc.identifier.citationFinal results of NAPOLI-1: a phase 3 study of nal-IRI (MM-398) ± 5-fluorouracil and leucovorin (5-FU/LV) vs 5-FU/LV in metastatic pancreatic cancer (mPAC) previously treated with gemcitabine-based therapy 2016, 27(suppl 6):622PD Annals of Oncologyen
dc.identifier.issn0923-7534
dc.identifier.issn1569-8041
dc.identifier.doi10.1093/annonc/mdw371.14
dc.identifier.urihttp://hdl.handle.net/10541/620303
dc.language.isoenen
dc.relation.urlhttps://academic.oup.com/annonc/article/2799369/Finalen
dc.rightsArchived with thanks to Annals of Oncologyen
dc.titleFinal results of NAPOLI-1: a phase 3 study of nal-IRI (MM-398) ± 5-fluorouracil and leucovorin (5-FU/LV) vs 5-FU/LV in metastatic pancreatic cancer (mPAC) previously treated with gemcitabine-based therapy.en
dc.typeMeetings and Proceedingsen
dc.contributor.departmentNational Institute of Cancer Research, National Health Research Institutes,Tainan, Taiwanen
dc.identifier.journalAnnals of Oncologyen


This item appears in the following Collection(s)

Show simple item record